Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations

Br J Haematol. 2003 Mar;120(6):1062-5. doi: 10.1046/j.1365-2141.2003.04194.x.

Abstract

Seventeen patients with therapy-related myelodysplastic syndrome/acute myeloid leukaemia (t-MDS/AML) were examined for aberrant p15 gene methylation by methylation-specific polymerase chain reaction. Ten patients (58%) showed p15 methylation, which was significantly related to monosomy/deletion of chromosome 7q, but not to antecedent chemotherapy, blast count, leukaemic evolution or survival. In three of six patients with marrow samples obtained prior to the diagnosis of t-MDS/AML, p15 methylation predated disease development by up to 2 years. Bone marrow transplantation led to the disappearance of p15 methylation in one patient. These results showed that p15 methylation was an early event in the evolution of some t-MDS/AML patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Bone Marrow Transplantation
  • Cell Cycle Proteins*
  • Cyclin-Dependent Kinase Inhibitor p15
  • DNA Methylation
  • Female
  • Humans
  • Leukemia, Myeloid / genetics
  • Leukemia, Myeloid / metabolism*
  • Leukemia, Myeloid / therapy
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / genetics
  • Myelodysplastic Syndromes / metabolism*
  • Myelodysplastic Syndromes / therapy
  • Polymerase Chain Reaction / methods
  • Promoter Regions, Genetic*
  • Time Factors
  • Transcription Factors / genetics*
  • Tumor Suppressor Proteins*

Substances

  • CDKN2B protein, human
  • Cell Cycle Proteins
  • Cyclin-Dependent Kinase Inhibitor p15
  • Transcription Factors
  • Tumor Suppressor Proteins